iBio came to investors’ attention due to the IBIO-201 vaccine for COVID-19 treatment. Additionally, being listed on Russel’s 2000 and 3000 indexes made its stock soar in June. That time all the coronavirus stocks have rocketed by their updates regarding the vaccine development.
August becomes not so good month for iBio even though IBIO-201 is under the clinical development stage. Nevertheless, Thursday brings hope in the stock’s rise towards, maybe $5. Not so big corporation becomes overvalued by over $350 million.
Cash burning iBio is still not capable to make earnings so long term investors may stay away until first earnings are seen on reports. Gamblers are always welcome to trade the cheap IBIO in NYSE.
Finance and Tech Contributor